Search Results

240 results for java

What the Latest Controversy Really Means for SAVA Stock

Headlines and controversy notwithstanding, consider SAVA stock to be one of the more promising biotech plays out there.

Cassava Sciences (SAVA) Stock Pops on Positive Results in Simufilam Trial

SAVA stock jumped 9% on Wednesday after Casava Sciences shared promising results of a clinical trial of its Alzheimer’s treatment.

3 Growth Stocks That Could Be Multibaggers in the Making: February Edition

Ambitious growth plans backed by solid execution will support these growth stocks soaring to multibagger status.

These Are the Top Reasons You Should Load Up on Cassava Sciences Stock

At the moment, there’s no cure for Alzheimer’s, but Cassava Sciences is working to wipe it out for good making SAVA stock a buy here.

3 Restaurant Stocks to Buy on the Dip: July 2024

These restaurant stocks showing solid same-store sales growth have been unfairly punished in the ongoing correction.

How High Can SAVA Stock Go Once the Controversy Clears?

If a reproduced SEC letter concerning Cassava Sciences’ clearance is legit, SAVA stock could head much higher.

3 Brilliant Blue-Chip Stocks for Lucrative Long-Term Growth

Why Is Cassava Sciences (SAVA) Stock Up 10% Today?

Cassava Sciences has completed part of an important Alzheimer’s disease treatment trial. Here’s why SAVA stock may rise even more soon.

Tread Carefully Before Pulling the Trigger on Cassava Sciences

While SAVA stock is intriguing based on the underlying Alzheimer’s treatment proposal, this market has an extremely high failure rate.

SAVA Stock: Cassava Sciences Extends Simufilam Trials as Much as 36 Months

Cassava Sciences has announced plans to extend trials for its Alzheimer’s treatment drug. This news isn’t helping SAVA stock.

SAVA Stock: What Is Going on With Red-Hot Cassava Sciences Today?

Today, Cassava Sciences initially soared on the announcement of some positive preliminary data, before SAVA stock began selling off.

The 3 Best Restaurant Stocks to Buy in June 2024

Investors looking for the best restaurant stocks to buy this summer should check out these three fast casual food chains that are heating up.

Don’t Let Misconduct Allegations Cloud Your Perception of SAVA Stock

It’s easy to get mired in the controversy surrounding Cassava Sciences, but distracted SAVA stock traders might miss an opportunity.

GRAB Stock: What to Know About the Acquisition Putting Grab in the Spotlight Today

Shares of GRAB stock are in the red after the company announced plans to buy Jaya Grocer, a popular supermarket chain based in Malaysia.

Does Cassava Sciences and Its Alzheimer’s Drug Really Have What It Takes?

Can Cassava Sciences’ Simufilam drug really treat Alzheimer’s? Who really knows. SAVA stock is pure speculation either way.

What to Do After Cassava Sciences Dropped Off a Cliff

Cassava Sciences posted positive clinical data but triggered a sell on the news event, as SAVA stock short sellers welcomed the drop.

Insiders Like Cassava Sciences, Which Might Be Good News

Insider transactions have historically proven quite prescient for the trajectory of SAVA stock, so what do they imply today?

Cassava Sciences News: SAVA Stock Surges 38% on Insider Buying

Cassava Sciences (SAVA) news for Friday concerning insider buying from leaders at the company has SAVA stock on the rise.

Twitter Inc (TWTR) Stock Needs a LOT More Than Activist Aid

Jana Partners can’t work miracles with Twitter Inc (TWTR), which is why it took only a small stake and some call options in Twitter stock.

SAVA Stock: 12 Things for Investors to Know About Cassava Sciences as Shares Soar

Cassava Sciences (SAVA) stock is on the rise Wednesday after revealing interim results from a recent Alzheimer’s disease clinical trial.

New SAVAW Warrants Are Trading After Cassava Sciences’ Distribution

Following a distribution, investors in Cassava Sciences and SAVA stock now have some warrants to factor into their models today.

Why Cassava Sciences Is Still a High-Risk Play

As it’s not set in stone that Cassava Sciences will be able to bring simulfilam to market, you should approach SAVA stock cautiously.

Cassava Sciences Just Returned to the Buy Zone

There’s no need to panic about SAVA stock, as Cassava Sciences just launched an important study focused on treating Alzheimer’s disease.

Cassava Sciences Is on the Ropes, so Watch for a Dip-Buy Opportunity

Amid a regulatory tug-of-war over a proposed Alzheimer’s disease treatment, SAVA stock has become a speculator’s playground.

9 – 10 of 240 results